Harvest Eli Lilly Enhanced High Income Shares ETF (LLHE.U)
- 9.490
- -0.030-0.32%
Harvest Eli Lilly Enhanced High Income Shares ETF (LLHE.U) News
Key Deals This Week: Flex, Nvidia, AbbVie and More
Healthcare August Recap: Moderna Jumps 156% as Biotech Shines; DaVita Sinks
3 Things to Look Out for on Tuesday
Catalyst Watch: Apple's High-stakes iPhone Event, Oracle, CPI, and the NFL Returns
Deal Dispatch: Nvidia Buys Hugging Face for $12.9 Billion, Barilla Acquires Goodles, Park Place Partners Bankruptcy
New On The BlockCalifornia utility company PG&E Corp. (NYSE:PCG) has launched a review of strategic alternatives, Reuters reported. The company said its board will evaluate regulatory, financial,
Most and Least Shorted Mid- to Mega-cap Healthcare Stocks at the End of August
Fraudulent Weight Loss Drugs: FDA Warns Against Mislabeled GLP-1 Medications
The U.S. Food and Drug Administration (FDA) on Tuesday warned patients and healthcare providers about severe health risks linked to unapproved and compounded glucagon-like peptide-1 (GLP-1) weight-
AtaiBeckley Says Hart-Scott-Rodino Waiting Period For Merger With Eli Lilly Expired On Aug 28, 2026; UK Competition Authority Has No Further Questions On Merger As Of August 21, 2026
As previously disclosed, AtaiBeckley Inc. (the "Company") entered into an Agreement and Plan of Merger, dated as of July 15, 2026 (the "Merger Agreement"), with Eli Lilly and Company, an Indiana
Eli Lilly and Co to acquire Merida for up to $2.875 billion, further expanding its immunology business
① Eli Lilly and Co announced the acquisition of biotech company Merida Biosciences for up to $2.875 billion in cash to strengthen its presence in the immunology sector, with the transaction expected to close by year-end; ② Merida’s core asset, MER511, is in Phase I clinical trials for Graves’ disease and thyroid eye disease.
4 Stocks to Watch on Monday: AMGN, LLY, ARM, and MSTR
After the GLP-1 weight-loss drug boom, Wall Street has set its sights on another pharmaceutical gold mine.
① Wall Street analysts believe that novel hair loss therapies represent an untapped gold mine, with a large number of consumers willing to pay out-of-pocket for better treatment options; ② It is estimated that approximately 50 million men and 30 million women in the United States are affected by hair loss, yet no new drugs have been approved in the market since the late 1990s.
Eli Lilly To Acquire Merida And Pay Up To $2.875B In Cash; Transaction Expected To Close In Q4 2026
Merida's antibody-engineering platform is designed to enable precise, durable removal of disease-causing antibodies, while preserving normal immune functionInitial Phase 1 data show MER511 achieved
Notable Healthcare Headlines for the Week: Veeva Systems, Boston Scientific in Focus
India has the second-highest number of diabetes cases globally; with monthly costs dropping to $14, why are GLP-1 weight-loss drugs still struggling to gain traction?
Although GLP-1 medications have been widely genericized in India, driving prices down to $14 per month, sales performance has fallen far short of expectations. Analysts point out that cultural perceptions equating obesity with prosperity, women’s lack of autonomy in healthcare spending, and regulatory hurdles complicating marketing efforts mean that penetrating India’s weight-loss drug market will require a prolonged strategic effort.
4 Stocks to Watch on Friday: MRNA, GILD, JBLU, and LLY
Eli Lilly Stock Pulls Back After Hitting Record Highs Last Week
Eli Lilly and Co. (NYSE:LLY) shares are trading lower Wednesday, pulling back after the stock notched an all-time high just last week, even as the company separately reported positive real-world
Eli Lilly Shines as Healthcare Giants Struggle on Growth Metrics
Eli Lilly Launches Oral Weight Loss Pill Foundayo in UK
Here's How Much You Would Have Made Owning Eli Lilly Stock In The Last 5 Years
Eli Lilly (NYSE:LLY) has outperformed the market over the past 5 years by 25.41% on an annualized basis producing an average annual return of 36.72%. Currently, Eli Lilly has a market capitalization
ProQR a New Buy at BoA on RNA-editing Platform